Practical Aspects of Renal Replacement Therapy

Bingel M. , Koch K.M. , Dinarello C.A. , Shaldon S. . Human interleukin-l production is enhanced by sodium acetate. Lancet 1987; I: 14–6.

Cheung A.K. , Chenoweth D.E. , Otsuka D. , Henderson L.W. . Compartmental distribution of complement activation products in artificial kidneys. Kindey Int 1986; 30: 74–80.

Colton C.K. . Analysis of membrane processes for blood purification. Blood Purif 1987; 5: 202–51.

Craddock P.R. , Fehr J. , Brigham K.L. , Kronenberg R.S. , Jacob H.S. . Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. N Engl J Med 1977; 296: 769–74.

Dinarello A.C. , Koch K.M. , Shaldon S. . Interleukin-l and its relevance in patients treated with hemodialysis. Kidney Int 1988; 33: S21–S26.

Dobos G.J. , Gawaz M.P. , Böhler J. . Antikoagulation bei kontinuierlichen veno-venösen Hämodialyseverfahren. Methoden und Probleme, Intensiv- und Notfallbehandlung 1993; 18: 129–36.

Geronemous R. , Schneider M. . Continuous arteriovenous hemodialysis. A new modality for the treatment of acute renal failure. Trans Am Soc Artif Intern Organs. 1984; 230: 610–3.

Hakim R.M. , Wingard R.L. , Parker R.A. . Effect of dialysis membrane in the treatment of patients with acute renal failure. New Engl J Med 1994; 331: 1338–42.

Hory B. , Saint-Hilier Y. , Perol J.C. . Prostacyclin as the sole antithrombic agent for acute renal failure hemodialysis. Nephrol 1983; 93: 202–4.

Maurin N. . Antithrombic management with a stable prostacyclin analogue during extracorporeal circulation. Contribut Nephrol 1991; 93: 205–9.

Schiffl H. , Lang S.M. , König A. , Strasser T. , Haider M.C. , Held E. . Biocompatible membranes in acute renal failure: prospective case-controlled study. Lancet 1994; 344: 570–2.

Schrader J. , Stibbe W. , Armstrong V.W. . Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration. Kidney Int 1988; 33: 890–6.

Schrader J. , Scheler F. . Coagulation disorders in acute renal failure and anticoagulation during CAVH with standard heparin and with low molecular weight heparin. In: Sieberth H.G. , Mann H. , eds. Continuous arteriovenous hemofiltration (CAVH). Basel: Karger, 1985; 25.

Schwartz R.D. , Port F.K. . Preventing hemorrhage in high-risk hemodialysis. Regional versus low dose heparin. Kidney Int 1979; 16: 513–8.

Schwartz R.D. , Flamenbaum W. , Dubrow A. , Hall J.C. , Crow J.W. , Cato A. . Epoprostenol (PGI₂ Prostacyclin) during high risk hemodialysis - preventing further bleeding complications. J Clin Pharmacol 1988; 28: 818–25.

Vesconi S. . Sicignano A, De-Pietri P, et al. Continuous veno-venous hemofiltration in critically ill patients with multiple organ failure. Int J Artif Organs 1993; 16: 592–8.

Zobel G. , Ring E. , Kuttnig M. , Grubbauer H.M. . Five years experience with continuous extracorporeal renal support in pediatric intensive care. Int Care Med 1991; 17: 315–9.